English | 简体中文 | 繁體中文 | 한국어
 Press Releases
Tuesday, October 23, 2018
GAM Holding AG: Interim management statement for the three-month period to 30 September 2018
07:00 ET
Kværner ASA: Third quarter results 2018: results on plan, improved market outlook
06:58 ET
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed 00:30 ET
Monday, October 22, 2018
FERRATUM OYJ: Repayment of Ferratum Capital Germany GmbH bonds maturing in 2018 20:30 ET
POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET 19:15 ET
XPO Logistics Awarded National LTL Carrier of the Year by Transplace 18:00 ET
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer 16:30 ET
AIR Develops Advanced Probabilistic Model for Global Cyber Risks 14:29 ET
Statkraft AS: Release of third quarter results 2018 13:16 ET
XPO Logistics Named a Top 20 UK Company for Quality of Workplace Culture and Leadership
13:00 ET
Pöyry and Infosys jointly introduce an artificial intelligence framework for industry, utilities and infrastructure organisations 13:00 ET
Valmet to deliver BioTracTM biomass pretreatment system to Clariant in Romania 12:00 ET
Prosafe SE : Q3 2018 results and webcast on 6 November 2018 10:48 ET
CF&B Communication : Madrid "European Midcap Event" November 14, 2018 - 30 listed companies, 50 spanish investors in One-to-One 10:17 ET
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma 09:15 ET
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone 09:15 ET
Ratos AB: HENT signs contract worth approximately NOK 1bn 09:00 ET
Disclosure Under Chapter 9 Section 5 of the Securities Market Act (Capital Income Builder)
08:25 ET
AIR Develops Advanced Probabilistic Model for Global Cyber Risks 08:12 ET
CapMan to publish its January-September 2018 Interim Report on Thursday 1 November 2018
08:00 ET
BinckBank N.V. trading update third quarter 2018: "result in line with expectations"
07:15 ET
Medtronic Co-Founder Earl Bakken Passes Away at Age 94 04:57 ET
Sunday, October 21, 2018
Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours 11:00 ET
PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING 00:30 ET
Saturday, October 20, 2018
Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer 16:30 ET
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone 16:30 ET
Friday, October 19, 2018
Hubbell Incorporated Declares 9% Dividend Increase 16:01 ET
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC 16:00 ET
Schibsted ASA (SCHA/SCHB) - Invitation to the presentation of Q3 2018 Results 14:46 ET
XPO Logistics Named a Fortune Future 50 Company 13:00 ET
Browse Press Releases
Press Releases by Industry »
Press Releases by Language »
Multimedia Press Releases »
Events newsroom »
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: